Last updated on July 2019

Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

Brief description of study

This Phase 3 will describe the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine formulation in adults 65 years of age or older with prior pneumococcal vaccination

Clinical Study Identifier: NCT03835975

Find a site near you

Start Over

Clinical Research Consulting, LLC

Milford, CT United States
  Connect »